| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| Other Sizes |
| Targets |
(-)-Corey lactone diol does not have a direct biological target as a therapeutic agent. Rather, it is a synthetic intermediate used in the preparation of prostaglandin analogs. Prostaglandins target various receptors including EP, FP, IP, DP, and TP receptors. The compound itself is used as a building block for the synthesis of these bioactive molecules.
|
|---|---|
| ln Vitro |
In vitro, (-)-Corey lactone diol is not typically tested for biological activity as it is a synthetic intermediate. However, the prostaglandins synthesized from it exhibit a wide range of biological activities including smooth muscle contraction, vasodilation, platelet aggregation inhibition, and inflammation modulation. The compound's utility is in organic synthesis rather than direct biological assays.
|
| ln Vivo |
In vivo, (-)-Corey lactone diol itself is not administered as a drug. The prostaglandin analogs derived from it are used clinically for various indications including glaucoma, ulcer treatment, induction of labor, and management of cardiovascular diseases. The in vivo effects depend on the specific prostaglandin analog synthesized.
|
| Enzyme Assay |
For non-cellular enzyme/receptor binding assays, (-)-Corey lactone diol is not typically used. However, the prostaglandins synthesized from it can be assessed for receptor binding affinity using radioligand binding assays. The compound's purity and stereochemical integrity are assessed using analytical techniques such as HPLC, NMR, and polarimetry.
|
| Cell Assay |
For in vitro cell-based assays, (-)-Corey lactone diol is not typically used. Prostaglandins synthesized from it can be tested in cell-based assays to assess receptor activation, cAMP production, calcium mobilization, and other signaling pathways. The compound itself is used as a starting material for chemical synthesis.
|
| Animal Protocol |
For in vivo animal studies, (-)-Corey lactone diol is not administered directly. Prostaglandin analogs derived from it are tested in various animal models depending on the therapeutic indication. For example, ocular hypertension models for glaucoma, ulcer models for gastric protection, and cardiovascular models for vasodilation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties include solubility in organic solvents such as dichloromethane, ethyl acetate, and methanol. It is a solid and should be stored at -20°C under inert atmosphere to prevent degradation. The molecular weight and specific optical rotation are key characteristics. It is a chiral compound and should be handled with care to maintain stereochemical integrity.
|
| Toxicity/Toxicokinetics |
Toxicological data for (-)-Corey lactone diol itself is limited as it is not a drug. It is a synthetic intermediate and should be handled with standard laboratory safety precautions. The prostaglandins derived from it have well-established safety profiles depending on the specific analog.
|
| Additional Infomation |
(-)-corey lactone is a γ-lactone.
(-)-Corey lactone diol is a key chiral intermediate in prostaglandin synthesis. It is used for the preparation of natural prostaglandins and their analogs. The compound is essential for the synthesis of prostaglandin-based drugs used in ophthalmology, gastroenterology, and cardiology. It is a valuable tool in medicinal chemistry and drug development. |
| Molecular Formula |
C8H12O4
|
|---|---|
| Molecular Weight |
172.17848
|
| Exact Mass |
172.073
|
| CAS # |
32233-40-2
|
| PubChem CID |
2724453
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
406.6±25.0 °C at 760 mmHg
|
| Melting Point |
117-119 °C(lit.)
|
| Flash Point |
172.9±16.7 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.546
|
| LogP |
-2.18
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
12
|
| Complexity |
203
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1[C@H]([C@@H]([C@@H]2[C@H]1OC(=O)C2)CO)O
|
| InChi Key |
VYTZWRCSPHQSFX-GBNDHIKLSA-N
|
| InChi Code |
InChI=1S/C8H12O4/c9-3-5-4-1-8(11)12-7(4)2-6(5)10/h4-7,9-10H,1-3H2/t4-,5-,6-,7+/m1/s1
|
| Chemical Name |
(3aR,4S,5R,6aS)-5-hydroxy-4-(hydroxymethyl)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~580.79 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.52 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (14.52 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.8079 mL | 29.0394 mL | 58.0788 mL | |
| 5 mM | 1.1616 mL | 5.8079 mL | 11.6158 mL | |
| 10 mM | 0.5808 mL | 2.9039 mL | 5.8079 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
